Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy

Journal of Internal Medicine, 04/26/2012

The incorporation of oestrogen response elements (ERE) single–nucleotide polymorphisms into models with known predictors might improve outcome prediction in patients with prostate cancer receiving androgen–deprivation therapy.

Print Article Summary Cat 2 CME Report